Search Results
You are looking at 1 - 2 of 2 items for
- Author: Maria J Merino x
- Refine by access: All content x
Search for other papers by Myriem Boufraqech in
Google Scholar
PubMed
Search for other papers by Lisa Zhang in
Google Scholar
PubMed
Search for other papers by Meenu Jain in
Google Scholar
PubMed
Search for other papers by Dhaval Patel in
Google Scholar
PubMed
Search for other papers by Ryan Ellis in
Google Scholar
PubMed
Search for other papers by Yin Xiong in
Google Scholar
PubMed
Search for other papers by Mei He in
Google Scholar
PubMed
Search for other papers by Naris Nilubol in
Google Scholar
PubMed
Search for other papers by Maria J Merino in
Google Scholar
PubMed
Search for other papers by Electron Kebebew in
Google Scholar
PubMed
The expression and function of miR-145 in thyroid cancer is unknown. We evaluated the expression and function of miR-145 in thyroid cancer and its potential clinical application as a biomarker. We found that the expression of miR-145 is significantly downregulated in thyroid cancer as compared with normal. Overexpression of miR-145 in thyroid cancer cell lines resulted in: decreased cell proliferation, migration, invasion, VEGF secretion, and E-cadherin expression. miR-145 overexpression also inhibited the PI3K/Akt pathway and directly targeted AKT3. In vivo, miR-145 overexpression decreased tumor growth and metastasis in a xenograft mouse model, and VEGF secretion. miR-145 inhibition in normal primary follicular thyroid cells decreased the expression of thyroid cell differentiation markers. Analysis of indeterminate fine-needle aspiration samples showed miR-145 had a 92% negative predictive value for distinguishing benign from malignant thyroid nodules. Circulating miR-145 levels were significantly higher in patients with thyroid cancer and showed a venous gradient. Serum exosome extractions revealed that miR-145 is secreted. Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis.
Search for other papers by Maya B Lodish in
Google Scholar
PubMed
Search for other papers by Karen T Adams in
Google Scholar
PubMed
Search for other papers by Thanh T Huynh in
Google Scholar
PubMed
Search for other papers by Tamara Prodanov in
Google Scholar
PubMed
Search for other papers by Alex Ling in
Google Scholar
PubMed
Search for other papers by Clara Chen in
Google Scholar
PubMed
Search for other papers by Suzanne Shusterman in
Google Scholar
PubMed
Search for other papers by Camilo Jimenez in
Google Scholar
PubMed
Search for other papers by Maria Merino in
Google Scholar
PubMed
Search for other papers by Marybeth Hughes in
Google Scholar
PubMed
Search for other papers by Kendall W Cradic in
Google Scholar
PubMed
Search for other papers by Dragana Milosevic in
Google Scholar
PubMed
Search for other papers by Ravinder J Singh in
Google Scholar
PubMed
Search for other papers by Constantine A Stratakis in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Organ of Zuckerkandl paragangliomas (PGLs) are rare neuroendocrine tumors that are derived from chromaffin cells located around the origin of the inferior mesenteric artery extending to the level of the aortic bifurcation. Mutations in the genes encoding succinate dehydrogenase subunits (SDH) B, C, and D (SDHx) have been associated with PGLs, but their contribution to PGLs of the organ of Zuckerkandl PGLs is not known. We aimed to describe the clinical presentation of patients with PGLs of the organ of Zuckerkandl and investigate the prevalence of SDHx mutations and other genetic defects among them. The clinical characteristics of 14 patients with PGL of the organ of Zuckerkandl were analyzed retrospectively; their DNA was tested for SDHx mutations and deletions. Eleven out of 14 (79%) patients with PGLs of the organ of Zuckerkandl were found to have mutations in the SDHB (9) or SDHD (2) genes; one patient was found to have the Carney–Stratakis syndrome (CSS), and his PGL was discovered during surgery for gastrointestinal stromal tumor. Our results show that SDHx mutations are prevalent in pediatric and adult PGLs of the organ of Zuckerkandl. Patients with PGLs of the organ of Zuckerkandl should be screened for SDHx mutations and the CSS; in addition, asymptomatic carriers of an SDHx mutation among the relatives of affected patients may benefit from tumor screening for early PGL detection.